Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

Journal of Clinical Oncology

Volumn 19, Issue 13, 2001, Pages 3244-3254

  Sievers, E L ^a   Larson, R A ^a   Stadtmauer, E A ^a   Estey, E ^a   Lowenberg B ^a   Dombret, H ^a   Karanes, C ^a   Theobald, M ^a   Bennett, J M ^a   Sherman, M L ^a   Berger, M S ^a   Eten, C B ^a   Loken, M R ^a   Van Dongen, J J M ^a   Bernstein, I D ^a   Appelbaum, F R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

EID: 0035397980     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.13.3244     Document Type: Article

References (34)

1. Acute myeloid leukemia
2. Estimate of overall treatment results in acute non-lymphocytic leukemia based on age-specific rates of incidence and of complete remission
3. What is the best induction regime for acute myelogenous leukemia?
4. The treatment of adult acute myeloid leukemia
5. New chemotherapeutic agents in acute myeloid leukemia
6. Carboplatin infusion in relapsed and refractory acute myeloid leukemia: A Southwest Oncology Group trial
7. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial
8. Response to salvage therapy and survival after relapse in acute myelogenous leukemia
9. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: A retrospective single-center study
10. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD9) in 150 patients with relapse after standardized first line therapy
11. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period
12. A: Results of therapy for acute myeloid leukemia in first relapse
13. Time sequential chemotherapy for advanced acute myeloid leukemia
14. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience
15. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia
16. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison
17. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia: A Southeastern Cancer Study Group trial
18. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: A multicenter randomized placebo-controlled trial (EMA91 trial)
19. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia
20. Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia
21. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
22. Expression of normal myeloid-associated antigens by acute leukemia cells
23. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia
24. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide
25. The use of radiolabeled anti-CD 33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia
26. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model
27. Calicheamicin gammal I and DNA: Molecular recognition process responsible for site-specificity
28. Anti-CD33 calicheamicin hybrid conjugates for the treatment of acute myelogenous leukemia
29. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD 33 calicheamicin immunoconjugate
30. Biologic and genetic features of acute myelogenous leukemia: New insights for therapy
31. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDRI) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy - A Southwest Oncology Group study
32. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
33. Continuous cultures of fused cells secreting antibody of predefined specificity
34. Monoclonal antibody-based therapies for hematologic malignancies